AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7002949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 0.1 N HCl
Number of subjects: 16
Study 7002949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 30 g glucose
Number of subjects: 16
Study 7002949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose-acid combination
Number of subjects: 16
Study 7002949 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal 20 g glucose
Number of subjects: 16
Study 7002949 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal 75 cc 0.1 N HCl
Number of subjects: 16
Study 7002949 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose-acid combination
Number of subjects: 16
Study 7002949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose-acid load
Number of subjects: 16
Study 31796827 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of 1-3 mA current intensity for 15-30 minutes
Number of subjects: 16
Study 27680219 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard/low dose regimen starting at 70% of the minimal erythema dose (MED) with 20% dose increments
Number of subjects: 15
Study 27680219 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose regimen starting at 200% MED with 25% increments
Number of subjects: 15
Study 25874255 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthwash containing Baccharis dracunculifolia
Number of subjects: 0
Study 25874255 — intervention group
Group type: COMPARATOR
Intervention: Other mouthwashes
Number of subjects: 0
Study 23806017 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountable Justifications
Number of subjects: 269
Study 23806017 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested Alternatives
Number of subjects: 269
Study 23806017 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Comparison
Number of subjects: 269
Study 22954754 — intervention group
Group type: EXPERIMENTAL
Intervention: RIS2mg+PIM20mg
Number of subjects: 423
Study 22954754 — intervention group
Group type: COMPARATOR
Intervention: RIS2mg+placebo
Number of subjects: 423
Study 22954754 — intervention group
Group type: COMPARATOR
Intervention: RIS6mg+placebo
Number of subjects: 423
Study 22954754 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL2mg+PIM20mg
Number of subjects: 423
Study 22954754 — intervention group
Group type: COMPARATOR
Intervention: HAL2mg+placebo
Number of subjects: 423
Study 19955881 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Tailored Intervention (CTI)
Number of subjects: 185
Study 19955881 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Message Intervention (TMI)
Number of subjects: 185
Study 19955881 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 185
Study 17571000 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT)
Number of subjects: 278
Study 17571000 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Wavelength Automated Perimetry (SWAP)
Number of subjects: 278
Study 17571000 — intervention group
Group type: COMPARATOR
Intervention: Standard Automated Perimetry (SAP)
Number of subjects: 278
Study 15823771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg sachet for suspension
Number of subjects: 72
Study 15823771 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg capsule
Number of subjects: 72
Study 15823771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg sachet for suspension
Number of subjects: 72
Study 15823771 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg capsule
Number of subjects: 72
Study 11682319 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9466101 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.5% plain bupivacaine
Number of subjects: 96
Study 9466101 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.9% saline with 5 mg diamorphine
Number of subjects: 96
Study 9466101 — intervention group
Group type: COMPARATOR
Intervention: 20 mL 0.9% saline (control)
Number of subjects: 96
Study 8180744 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (1200 mg/day)
Number of subjects: 40
Study 8180744 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg/day)
Number of subjects: 40
Study 3286360 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily
Number of subjects: 57
Study 3286360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31747236 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100 mcg/25 mcg
Number of subjects: 16485
Study 31747236 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 100 mcg
Number of subjects: 16485
Study 31747236 — intervention group
Group type: EXPERIMENTAL
Intervention: VI 25 mcg
Number of subjects: 16485
Study 31747236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485
Study 27940009 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 100
Study 27940009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26445112 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1 pmol × kg(‐1) × min(‐1))
Number of subjects: 15
Study 26445112 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.86 pmol × kg(‐1) × min(‐1))
Number of subjects: 15
Study 26445112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (3 pmol × kg(‐1) × min(‐1))
Number of subjects: 15
Study 26445112 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon + GLP-1 (same doses)
Number of subjects: 15
Study 26445112 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study 26445112 — intervention group
Group type: EXPERIMENTAL
Intervention: All peptide infusions
Number of subjects: 15
Study 26445112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin, GLP-1, and GLP-1 + glucagon
Number of subjects: 15
Study 26445112 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 15
Study 24019546 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT) following vaginal radium brachytherapy (n = 288)
Number of subjects: 568
Study 24019546 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy alone (n = 280)
Number of subjects: 568
Study 24019546 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT)
Number of subjects: 568
Study 22010012 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80 to 120 mg per day for 4 weeks, followed by 2 weeks of rest, repeated for 1 year)
Number of subjects: 0
Study 22010012 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study 19564224 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month structured outpatient intervention using brief psychodynamic psychotherapy
Number of subjects: 87
Study 19564224 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment recommended by the Chilean Ministry of Health
Number of subjects: 87
Study 16458130 — intervention group
Group type: EXPERIMENTAL
Intervention: upstream tirofiban
Number of subjects: 93
Study 16458130 — intervention group
Group type: COMPARATOR
Intervention: downstream high-dose bolus tirofiban
Number of subjects: 93
Study 16458130 — intervention group
Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 93
Study 15303805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular corticosteroid injections (ICIs)
Number of subjects: 18
Study 10799192 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal antimicrobial mesh (MycroMesh)
Number of subjects: 40
Study 10799192 — intervention group
Group type: COMPARATOR
Intervention: Vaginal wall sling
Number of subjects: 40
Study 8867875 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 microgram/kg)
Number of subjects: 0
Study 8867875 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 1617766 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 159
Study 1617766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 6380197 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 6
Study 6380197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30661220 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched tomato juice (200g with 1g ethanolic extract)
Number of subjects: 26
Study 30661220 — intervention group
Group type: COMPARATOR
Intervention: Standard tomato juice (200g)
Number of subjects: 26
Study 28385329 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (BP) - 600,000 IU for children ≤27kg and 1,200,000 IU for children ≥27kg, administered every two weeks for six months.
Number of subjects: 350
Study 28385329 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZT) - 250mg for children ≤25kg and 500mg for children ≥25kg, administered once weekly for six months.
Number of subjects: 350
Study 26367377 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 12
Study 26367377 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 12
Study 23233715 — intervention group
Group type: EXPERIMENTAL
Intervention: modified FOLFOX6 plus bevacizumab (5 mg/kg) once every 2 weeks for 12 months
Number of subjects: 2673
Study 23233715 — intervention group
Group type: COMPARATOR
Intervention: modified FOLFOX6 (control group) once every 2 weeks for 6 months
Number of subjects: 2673
Study 21450639 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk test (6MWT)
Number of subjects: 88
Study 19587109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse intervention
Number of subjects: 766
Study 17372327 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal waist circumference
Number of subjects: 266
Study 17372327 — intervention group
Group type: COMPARATOR
Intervention: Umbilical waist circumference
Number of subjects: 266
Study 15193891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic women with lower acculturation levels
Number of subjects: 767
Study 15193891 — intervention group
Group type: COMPARATOR
Intervention: Highly acculturated Hispanic women and non-Hispanic white women
Number of subjects: 767
Study 15193891 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic white women
Number of subjects: 767
Study 11836798 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via Clickhaler (100 microg)
Number of subjects: 61
Study 11836798 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via pMDI plus VHC (100 microg)
Number of subjects: 61
Study 11836798 — intervention group
Group type: EXPERIMENTAL
Intervention: Clickhaler
Number of subjects: 61
Study 11836798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 61
Study 10429840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg/day by oral inhalation for 28 days
Number of subjects: 138
Study 10429840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 7724714 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for major depression in primary care setting
Number of subjects: 0
Study 7724714 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to mental health facility
Number of subjects: 0
Study 7724714 — intervention group
Group type: EXPERIMENTAL
Intervention: Other conditions
Number of subjects: 0
Study 1823578 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant compound (2 tablets daily for 3 weeks)
Number of subjects: 15
Study 1823578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7033994 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily dosage of carbamazepine (mean dose 13.9 mg/dg)
Number of subjects: 14
Study 7033994 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dosage of carbamazepine
Number of subjects: 14
Study 7033994 — intervention group
Group type: COMPARATOR
Intervention: Divided daily doses of carbamazepine (2 to 3 times daily)
Number of subjects: 14
Study 6145618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafenolol (beta-blocker more beta 1-selective than metoprolol)
Number of subjects: 0
Study 6145618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (selective beta 1-stimulating agent)
Number of subjects: 0
Study 6145618 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0
Study 30463830 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 160
Study 30463830 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 160
Study 27342377 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined epilepsy nurse role
Number of subjects: 320
Study 27342377 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 320
Study 25525601 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 200
Study 25525601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breast stimulation)
Number of subjects: 200
Study 23312051 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (3 g/day, 1 g three times a day during meals for 6 months)
Number of subjects: 0
Study 23312051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20412373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 984
Study 20412373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 18709812 — intervention group
Group type: COMPARATOR
Intervention: Lubricant gel
Number of subjects: 117
Study 18709812 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal lidocaine gel
Number of subjects: 117
Study 18709812 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic blockage with 1% lidocaine
Number of subjects: 117
Study 18709812 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 117
Study 18709812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest anxiety
Number of subjects: 117
Study 21966755 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day (group 1)
Number of subjects: 18
Study 21966755 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day plus chlormadinone 1 mg/day (group 2)
Number of subjects: 18
Study 12962026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) administered every month or two months for more than half a year
Number of subjects: 0
Study 12962026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9869584 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day regimen of oral azithromycin (500 mg/day for days 1 to 3)
Number of subjects: 12
Study 9869584 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day regimen of oral azithromycin (500 mg on day 1 and 250 mg/day for days 2 to 5)
Number of subjects: 12
Study 9869584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens of oral azithromycin
Number of subjects: 12
Study 8699584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (n = 20)
Number of subjects: 39
Study 8699584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study 1743787 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 18
Study 6849849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel (synthetic hydrophilic polymer)
Number of subjects: 48
Study 6849849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study 30865288 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based daily evaluation of mixed symptoms and irritability
Number of subjects: 84
Study 30383906 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m2 on days 8 and 15 plus CC-486 200 mg daily on days 1 to 14
Number of subjects: 161
Study 30383906 — intervention group
Group type: COMPARATOR
Intervention: single-agent nab-paclitaxel 100 mg/m2 on days 1 and 8
Number of subjects: 161
Study 27271664 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 g of olive fruit polyphenol-enriched yogurt with 50 mg of encapsulated olive polyphenols
Number of subjects: 16
Study 27271664 — intervention group
Group type: COMPARATOR
Intervention: 400 g of plain yogurt
Number of subjects: 16
Study 23485658 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education and administration of intramuscular diclofenac Na 75 mg regardless of pain reporting in the first two postoperative hours
Number of subjects: 70
Study 23485658 — intervention group
Group type: COMPARATOR
Intervention: Control group received no preoperative education and analgesics only upon pain reporting
Number of subjects: 70
Study 21824010 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT treatment (MPD plus RCT)
Number of subjects: 40
Study 21824010 — intervention group
Group type: COMPARATOR
Intervention: Control group (MPD plus SPC)
Number of subjects: 40
Study 19236688 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation (ATC)
Number of subjects: 180
Study 19236688 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 180
Study 17990199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based Rehabilitation
Number of subjects: 94
Study 17990199 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Number of subjects: 94
Study 17990199 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 94
Study 16400902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% olopatadine nasal spray
Number of subjects: 565
Study 16400902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% olopatadine nasal spray
Number of subjects: 565
Study 16400902 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine nasal spray (0.4% and 0.6%)
Number of subjects: 565
Study 12146535 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed implantation (Group 2)
Number of subjects: 66
Study 12146535 — intervention group
Group type: COMPARATOR
Intervention: Immediate implantation (Group 1)
Number of subjects: 66
Study 12146535 — intervention group
Group type: COMPARATOR
Intervention: Late implantation (Group 3)
Number of subjects: 66
Study 9532321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (42 mcg/nostril t.i.d.)
Number of subjects: 219
Study 9532321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (84 mcg/nostril t.i.d.)
Number of subjects: 219
Study 9532321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline vehicle)
Number of subjects: 219
Study 7977225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 1022
Study 7977225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 1022
Study 7977225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine or Mesalazine
Number of subjects: 1022
Study 3288292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g pulsed methylprednisolone
Number of subjects: 71
Study 3288292 — intervention group
Group type: COMPARATOR
Intervention: 500 mg pulsed methylprednisolone
Number of subjects: 71
Study 3288292 — intervention group
Group type: COMPARATOR
Intervention: 40 mg pulsed methylprednisolone
Number of subjects: 71
Study 3288292 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 71
Study 12305415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dienestrol following each intercourse
Number of subjects: 30
Study 12305415 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg dienestrol and 0.2 mg ethynodiol‐diacetate
Number of subjects: 30
Study 30684048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antiemetics (primarily prokinetics such as metoclopramide and domperidone)
Number of subjects: 112
Study 30684048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetics (metoclopramide and domperidone)
Number of subjects: 112
Study 30684048 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Number of subjects: 112
Study 30684048 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic antipsychotics
Number of subjects: 112
Study 30684048 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 112
Study 30684048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetics (at occurrence of OINV)
Number of subjects: 112
Study 27485808 — intervention group
Group type: EXPERIMENTAL
Intervention: Floorball training (FG)
Number of subjects: 39
Study 27485808 — intervention group
Group type: COMPARATOR
Intervention: Petanque group (PG)
Number of subjects: 39
Study 25723472 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 541
Study 25723472 — intervention group
Group type: COMPARATOR
Intervention: Control (lopinavir/ritonavir with nucleoside/nucleotide reverse transcriptase inhibitors)
Number of subjects: 541
Study 25723472 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL
Number of subjects: 541
Study 24565238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine S75-R25 with epinephrine 1:200,000 (bupi)
Number of subjects: 44
Study 24565238 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (ropi)
Number of subjects: 44
Study 20971744 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 266
Study 20971744 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 266
Study 19212877 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX267
Number of subjects: 0
Study 17207326 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant LH (rLH) supplementation
Number of subjects: 5
Study 17207326 — intervention group
Group type: COMPARATOR
Intervention: Control (no rLH supplementation)
Number of subjects: 5
Study 14759456 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous retrograde cold blood cardioplegia
Number of subjects: 70
Study 14759456 — intervention group
Group type: COMPARATOR
Intervention: Intermittent retrograde cold blood cardioplegia
Number of subjects: 70
Study 11759784 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity and nutrition interventions (EI)
Number of subjects: 0